Investor Relations

Latest Financial Results

Q2 2024

Quarterly Results

Ended Jun 30, 2024

Stock Information

NYSE American

ATNM

Price

Change

Volume

Market Cap

52 week Low/High

Day Low/High

Company Overview

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs not addressed by traditional cancer therapies. Actinium's current clinical pipeline is led by ARCs or Antibody Radiation-Conjugates that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Actinium's targeted conditioning ARCs seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Iomab-ACT, low dose I-131 apamistamab is being studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center. In addition, we are leaders in the field of Actinium-225 alpha therapies. Actimab-A, our clinical stage CD33 targeting ARC alpha therapy has been studied in nearly 150 patients including our ongoing combination trials with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 220 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC  to bolster our pipeline for strategic purposes.

Contact Information

Investor Relations
Actinium Pharmaceuticals, Inc.
100 Park Avenue, 23rd Floor
New York, NY 10017
Investorrelations@actiniumpharma.com

Transfer Agent
Securities Transfer Corporation
2901 N. Dallas Parkway
Suite 380
Plano, Texas 75093
T: (469) 633-0101
F: (469) 633-0088
www.stctransfer.com